electroCore, Inc.
NASDAQ:ECOR

Watchlist Manager
electroCore, Inc. Logo
electroCore, Inc.
NASDAQ:ECOR
Watchlist
Price: 16.26 USD -7.19% Market Closed
Market Cap: 106.5m USD
Have any thoughts about
electroCore, Inc.?
Write Note

electroCore, Inc.
Pre-Tax Income

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

electroCore, Inc.
Pre-Tax Income Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Pre-Tax Income CAGR 3Y CAGR 5Y CAGR 10Y
electroCore, Inc.
NASDAQ:ECOR
Pre-Tax Income
-$12.8m
CAGR 3-Years
13%
CAGR 5-Years
24%
CAGR 10-Years
N/A
Becton Dickinson and Co
NYSE:BDX
Pre-Tax Income
$2B
CAGR 3-Years
6%
CAGR 5-Years
12%
CAGR 10-Years
3%
Boston Scientific Corp
NYSE:BSX
Pre-Tax Income
$2.2B
CAGR 3-Years
20%
CAGR 5-Years
17%
CAGR 10-Years
36%
Stryker Corp
NYSE:SYK
Pre-Tax Income
$4.2B
CAGR 3-Years
24%
CAGR 5-Years
13%
CAGR 10-Years
14%
Abbott Laboratories
NYSE:ABT
Pre-Tax Income
$6.8B
CAGR 3-Years
-6%
CAGR 5-Years
12%
CAGR 10-Years
11%
Intuitive Surgical Inc
NASDAQ:ISRG
Pre-Tax Income
$2.4B
CAGR 3-Years
8%
CAGR 5-Years
11%
CAGR 10-Years
15%
No Stocks Found

electroCore, Inc.
Glance View

Market Cap
105.8m USD
Industry
Health Care

electroCore, Inc. engages in the provision of non-invasive vagus nerve stimulation (nVNS) therapy. The company is headquartered in Rockaway, New Jersey and currently employs 52 full-time employees. The company went IPO on 2018-06-22. nVNS is a platform for bioelectronic medical therapy that modulates neurotransmitters and immune function through its effects on both the peripheral and central nervous systems. The firm is providing gammaCore device for the treatment of cluster headache and migraine, the acute treatment of migraine and episodic cluster headache, the acute and preventive treatment of migraines in adolescents, and paroxysmal hemicrania and hemicrania continua in adults. gammaCore permits patients to self-administer doses of nVNS on an as-needed basis for treatment of prevent multiple types of headache pain via the vagus nerve. The gammaCore therapy is also used to treat primary headache, including migraine, cluster headache (CH), hemicrania continua and paroxysmal hemicrania (PH) and coronavirus (COVID-19).

ECOR Intrinsic Value
18.49 USD
Undervaluation 12%
Intrinsic Value
Price

See Also

What is electroCore, Inc.'s Pre-Tax Income?
Pre-Tax Income
-12.8m USD

Based on the financial report for Sep 30, 2024, electroCore, Inc.'s Pre-Tax Income amounts to -12.8m USD.

What is electroCore, Inc.'s Pre-Tax Income growth rate?
Pre-Tax Income CAGR 5Y
24%

Over the last year, the Pre-Tax Income growth was 38%. The average annual Pre-Tax Income growth rates for electroCore, Inc. have been 13% over the past three years , 24% over the past five years .

Back to Top